PDL BioPharma, Inc. PDLIV
NASDAQ
Recommendation
Dividend Power Score
Day's Range
Latest Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
--
| 08/31/2020 | 06/30/2020 | 03/31/2020 | |||
|---|---|---|---|---|---|
| Net Income | -- | -49.97M | -31.72M | ||
| Total Depreciation and Amortization | -- | 878.00K | 996.00K | ||
| Total Amortization of Deferred Charges | -- | 205.00K | 280.00K | ||
| Total Other Non-Cash Items | -- | 41.46M | 28.61M | ||
| Change in Net Operating Assets | -- | -5.64M | -17.18M | ||
| Cash from Operations | -- | -13.06M | -19.02M | ||
| Capital Expenditure | -- | -142.00K | -93.00K | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | 11.40M | 13.57M | ||
| Cash from Investing | -- | 11.26M | 13.48M | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | 0.00 | -18.85M | ||
| Issuance of Common Stock | -- | 461.00K | -- | ||
| Repurchase of Common Stock | -- | -20.15M | -19.23M | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | 0.00 | -3.02M | ||
| Cash from Financing | -- | -19.69M | -41.09M | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -- | -21.50M | -46.63M | ||